Time limits apply in Texas. Find out if you still qualify.
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Verified against court and regulatory records · No upfront fees · Your information is never sold
Statute of limitations — Texas
Texas Civil Practice and Remedies Code § 16.003 provides a 2-year statute of limitations for personal injury claims. The discovery rule applies for pharmaceutical injuries — the limitations period begins when the plaintiff discovers or reasonably should have discovered the connection between Elmiron and vision loss. Texas also has a 15-year statute of repose for product liability claims under § 16.012, which may affect patients who started Elmiron before 2011.
2 years from discovery of Elmiron-related vision injury
Filing venue
Where to File in Texas
Federal Elmiron cases from Texas are transferred to the MDL in the District of New Jersey (MDL No. 2973). Texas state court claims may proceed in Harris County (Houston), Dallas County, or Bexar County (San Antonio) district courts. Texas applies a Daubert-style reliability standard for expert testimony under Texas Rule of Evidence 702. The 15-year statute of repose under § 16.012 is a concern for patients who began Elmiron use before 2011, though arguments exist that continuous use restarts the repose period.
Texas data
Exposure in Texas
Texas population — second-largest state with major urology centers at UT Southwestern, MD Anderson, and Baylor College of Medicine
30.5 million
Source: U.S. Census Bureau 2024
Standard Elmiron dosing — three 100mg capsules daily, often prescribed for years or decades, with cumulative exposure linked to greater retinal damage risk
300 mg/day
Source: FDA-approved prescribing information
Annual peak U.S. sales of Elmiron before generic competition — Janssen marketed the drug aggressively without retinal toxicity warnings for over two decades
$500+ million
Source: Johnson & Johnson financial reports
Keep reading